Thomas Haughey Acquires 2,500 Shares of ANI Pharmaceuticals Inc (ANIP) Stock

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Director Thomas Haughey bought 2,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $69.30 per share, for a total transaction of $173,250.00. Following the acquisition, the director now directly owns 6,291 shares of the company’s stock, valued at $435,966.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of NASDAQ ANIP traded down $0.63 during mid-day trading on Wednesday, reaching $69.14. 145,438 shares of the company traded hands, compared to its average volume of 87,476. ANI Pharmaceuticals Inc has a fifty-two week low of $36.92 and a fifty-two week high of $74.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The firm has a market capitalization of $836.09 million, a PE ratio of 15.00 and a beta of 2.37.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The business had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. During the same quarter last year, the business earned $1.32 earnings per share. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. Sell-side analysts anticipate that ANI Pharmaceuticals Inc will post 5.97 earnings per share for the current fiscal year.

ANIP has been the topic of a number of recent research reports. Raymond James set a $73.00 target price on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 28th. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price target on the stock in a report on Thursday, March 28th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $84.25.

Several hedge funds and other institutional investors have recently bought and sold shares of ANIP. Man Group plc increased its stake in shares of ANI Pharmaceuticals by 175.0% during the third quarter. Man Group plc now owns 8,338 shares of the specialty pharmaceutical company’s stock valued at $471,000 after acquiring an additional 5,306 shares during the period. MetLife Investment Advisors LLC grew its position in ANI Pharmaceuticals by 55.6% in the third quarter. MetLife Investment Advisors LLC now owns 6,140 shares of the specialty pharmaceutical company’s stock worth $347,000 after buying an additional 2,195 shares during the last quarter. AQR Capital Management LLC grew its position in ANI Pharmaceuticals by 21.9% in the third quarter. AQR Capital Management LLC now owns 9,792 shares of the specialty pharmaceutical company’s stock worth $554,000 after buying an additional 1,757 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in ANI Pharmaceuticals by 5.7% in the third quarter. TIAA CREF Investment Management LLC now owns 48,667 shares of the specialty pharmaceutical company’s stock worth $2,752,000 after buying an additional 2,635 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 1.6% in the third quarter. Vanguard Group Inc. now owns 522,813 shares of the specialty pharmaceutical company’s stock worth $29,559,000 after buying an additional 8,173 shares during the last quarter. Institutional investors and hedge funds own 60.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Thomas Haughey Acquires 2,500 Shares of ANI Pharmaceuticals Inc (ANIP) Stock” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/15/thomas-haughey-acquires-2500-shares-of-ani-pharmaceuticals-inc-anip-stock.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: FAANG Stocks

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.